Manufactured CAR T cells ready for infusion into a patient.

FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma

The Food and Drug Administration approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that has not responded to or has returned after at least four different prior cancer treatments. The approval is based, in part, on earlier clinical work led by James N. Kochenderfer, M.D., Senior Investigator in the Surgery Branch. Read more...

FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma
Schematic of SAR-seq methodology

Hotspots for DNA damage and repair in neurons identified

Mar 25, 2021

Researchers have pinpointed hotspots along the genome of neurons where endogenous, or internally driven, DNA breaks and repair accumulate. If the breaks are not repaired rapidly, they can lead to neuron dysfunction, degeneration and death. Read more...

HPV-16 E5 Oncoprotein

Clinical trial investigates vaccine to treat recurrent respiratory papillomatosis after surgery

Mar 24, 2021

Scott M. Norberg, D.O., Assistant Research Physician in the Genitourinary Malignancies Branch, is leading a study of PRGN-2012, an experimental therapeutic vaccine for adults with recurrent respiratory papillomatosis (RRP). RRP is a rare disorder caused by human papillomavirus. Read more...

AACR 2021 logo

AACR Annual Meeting - Session I

Mar 17, 2021

A number of CCR scientists will present their research at the AACR Annual Meeting. The virtual session I takes place April 10-15, 2021.  Read more...

mouse model of human colorectal cancer

New trial evaluates immunotherapy combinations in adults with advanced small bowel and colorectal cancers

Mar 15, 2021

Julius Strauss, M.D., Assistant Research Physician in the Laboratory of Tumor Immunology and Biology, is leading a clinical trial evaluating a combination of immunotherapy drugs to see if they can shrink advanced tumors of the small bowel, colon and rectum. Read more...

Milestones cover

New Milestones publication now available

Mar 15, 2021

Every year, the Center for Cancer Research makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestones, features some of our top scientific advances in the past year at CCR. These discoveries include two new FDA-approved therapies, insights into how to design RNA-targeted therapeutics and new ways to predict treatment outcomes in immunotherapy. Other major advances include the development of new computational tools – for identifying viruses in cancer genomes and to elucidate the consequences of DNA damage – and novel diagnostic tools – one to detect liver cancer, another to precisely detect prostate cancer.  Read more...

Human Natural Killer Cell

Clinical trial evaluates combination therapy for men with metastatic prostate cancer

Mar 11, 2021

Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is leading a study of an experimental treatment for men with two types of prostate cancer: one type that responds to hormone therapy and one that doesn’t.Read more...

chromosomes

New finding reveals how some cancers gain or lose chromosomes

Mar 9, 2021

Some cancers have an abnormal number of chromosomes, and patients with these cancers tend to have a worse prognosis. CCR researchers have uncovered how overexpression of just one protein can cause these chromosome abnormalities – hinting at a mechanism that could be therapeutically targeted. Read more...

sclerotic cGVHD skin

Drug lessens symptoms of severe chronic graft-versus-host disease

Mar 8, 2021

About half of patients who receive allogeneic stem cell transplants, a treatment for blood cancer, develop a difficult-to-treat condition called chronic graft-versus-host disease (cGVHD). CCR investigators have found that pomalidomide, an immune-modulating drug, can reduce symptoms in patients with severe cases of cGVHD. Read more...

figure 8 from publication

A key mechanism that fuels uncontrolled cell growth is uncovered in yeast

Feb 16, 2021

Scientists have long wondered how cancer cells use a protein complex, called TOR, to survive and proliferate in nutrient-poor conditions. Now, CCR researchers have discovered how a protein that is targeted by TOR drives this process, which holds important implications for understanding cancer and some genetic disorders. Read more...

RNA

Registration and abstract submission now open for RNA Biology Symposium

Feb 10, 2021

The symposium offers the opportunity to learn more about the current status of RNA biology in development and disease, share research with leading figures in the field and discuss the use and implications of these advances for clinical applications. Sessions Include: RNA Processing; RNA Structure and Mechanism; Non-Classical RNAs; and RNA Therapy. Learn more...

Pages